| Project/Area Number |
04557026
|
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | National Institute of Health, Dept.of Pathology |
|---|
Principal Investigator |
TAMURA Shinichi N.I.H Chief, 感染病理部, 室長 (20100084)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OGAWA Kouji kitasato Inst., 耳鼻咽喉科, 部長 (20160765)
KAMIYA Hitoshi Mie Hosp., 三重病院・小児感染症, 院長 (20024656)
AIZAWA Chikara Kitasato Inst., 技術部, 部長 (80072362)
KOJIMA Asato N.I.H, 感染病理部, 室長 (30100077)
KURATA Takeshi N.I.H, 感染病理部, 部長 (50012779)
|
|---|
| Project Period (FY) |
1992 – 1994
|
| Project Status |
Completed (Fiscal Year 1994)
|
| Budget Amount *help |
¥19,700,000 (Direct Cost: ¥19,700,000)
Fiscal Year 1994: ¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 1993: ¥5,500,000 (Direct Cost: ¥5,500,000)
Fiscal Year 1992: ¥11,300,000 (Direct Cost: ¥11,300,000)
|
|---|
| Keywords | influenza / intranasal vaccination / inactivated vaccine / adjuvant / heat-labile toxin / IgA / 交差感染阻止 |
|---|
| Research Abstract |
Natural influenza virus has been shown to be superior to the inactivated vaccine for inducing cross-protection against variants within a subtype of A type virus. The cross-protection induced by natural infection seems to be largely due to the induction of cross-reacting IgA antibodies in the respiratory tract. These facts suggest that the development of immunization procedure to stimulate mucosal IgA antibody production would improve the protective efficacy of the current inactivated vaccine. In this regard, intranasal immunization of inactivated vaccine has been advocated as means of inducing secretory IgA and systemic IgG antibodies against influenza. However, the intranasal immunization of inactivated vaccine alone cannot easily generate the secretory IgA antibodies. Under these circumstances, we attempted to inoculate intranasally the current inactivated vaccine together with a potent adjuvant, cholera toxin B subunit (CTB) containing 0.1% of CT,in mice. The results demonstrated that the nasal administration of the adjuvant-combined vaccine into mice can mimic the efficacy of live virus in inducing cross-protection against variant virus challenge. Moreover, we examined the effect of the intranasal immunization of the adjuvant-combined vaccine on IgA and HI antibody responses in humans. The results demonstrated that the adjuvant-combined vaccine can elicit significantly not only secretory IgA antibody but also serum HI antibody, as compared with vaccine alone, in humans.
|
